The unsustainable cost of cancer drugs

June 8, 2009- Interviewed by Steven Greer, MD

Leonard Saltz, MD, of Memorial Sloan-Kettering Cancer Center, discusses how the targeted cancer drugs developed within the last 5 years (Avastin, Tarceva, Sutent, Nexavar, etc) are escalating the total cost burden per cancer patient to unsustainable levels.

This entry was posted in - Opinion, - Policy, Congress, Memorial Sloan-Kettering, Oncology. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *